Evidence map›Paper›PMID 39567017›Full record

Trial reportMagnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine2025

Image-based Re-evaluation of the JCOG0911 Study Focusing on Tumor Volume and Survival, Disease Progression Diagnosis, and Radiomic Prognostication for Newly Diagnosed Glioblastoma.

Manabu Kinoshita, Yasutaka Fushimi, Tomohiko Masumoto, Keita Sasaki, Tetsuya Sekita, Atsushi Natsume, Toshihiko Wakabashi, Takashi Komori, Shunsuke Tsuzuki, Yoshihiro Muragaki and 30 more

Abstract readRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

40 authors.

Manabu KinoshitaDepartment of Neurosurgery, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
Yasutaka FushimiDepartment of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.
Tomohiko MasumotoDepartment of Diagnostic Radiology, Toranomon Hospital, Tokyo, Japan.
Keita SasakiJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Tetsuya SekitaJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Atsushi NatsumeThe Institute of Innovation for Future Society, Nagoya University, Nagoya, Aichi, Japan.
Toshihiko WakabashiDepartment of Neurosurgery, Nagoya Garden Clinic, Nagoya, Aichi, Japan.
Takashi KomoriDepartment of Laboratory Medicine and Pathology (Neuropathology), Tokyo Metropolitan Neurological Hospital, Fuchu, Tokyo, Japan.
Shunsuke TsuzukiDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Yoshihiro MuragakiDepartment of Neurosurgery, Tokyo Women's Medical University, Tokyo, Japan.
Kazuya MotomuraDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Ryuta SaitoDepartment of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Kenichi SatoDepartment of Neurosurgery, Nakamura Memorial Hospital, Sapporo, Hokkaido, Japan.
Takaaki BeppuDepartment of Neurosurgery, Iwate Medical University School of Medicine, Shiwa, Iwate, Japan.
Masamichi TakahashiDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Jun-Ichiro KurodaDepartment of Neurosurgery, Kumamoto University, Kumamoto, Kumamoto, Japan.
Yukihiko SonodaDepartment of Neurosurgery, Faculty of medicine, Yamagata University, Yamagata, Yamagata, Japan.
Keiichi KobayashiDepartment of Neurosurgery, Kyorin University Faculty of Medicine, Mitaka, Tokyo, Japan.
Kazuhiko MishimaDepartment of Neuro-Oncology/Neurosurgery, International Medical Center, Saitama Medical University, Hidaka, Saitama, Japan.
Koichi MitsuyaDivision of Neurosurgery, Shizuoka Cancer Center, Sunto, Shizuoka, Japan.
Fumiyuki YamasakiDepartment of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima, Japan.
Akihiro InoueDepartment of Neurosurgery, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
Tomoo MatsutaniDepartment of Neurosurgery, Chiba University Graduate School of Medicine, Chiba, Chiba, Japan.
Hideo NakamuraDepartment of Neurosurgery, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Shigeru YamaguchiDepartment of Neurosurgery, Hokkaido University, Sapporo, Hokkaido, Japan.
Eiichi IshikawaDepartment of Neurosurgery, Institute of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan.
Masato NakayaDepartment of Neurosurgery, Keio University School of Medicine, Tokyo, Japan.
Shota TanakaDepartment of Neurosurgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Kenta UjifukuDepartment of Neurosurgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Nagasaki, Japan.
Hiroyuki UchidaDepartment of Neurosurgery, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Kagoshima, Japan.
Masayuki KanamoriDepartment of Neurosurgery, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
Ryohei OtaniDepartment of Neurosurgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Noriyuki KijimaDepartment of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.
Namiko NishidaDepartment of Neurosurgery, Medical Research Institute Kitano Hospital, PIIF Tazuke-kofukai, Osaka, Osaka, Japan.
Atsuo YoshinoDepartment of Neurological Surgery, Nihon University School of Medicine, Tokyo, Japan.
Yohei MineharuDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.
Yoshiki ArakawaDepartment of Neurosurgery, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.
Haruhiko FukudaJCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Yoshitaka NaritaDepartment of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Members of Japan Clinical Oncology Group Brain Tumor Study Group (JCOG-BTSG)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo re-evaluate images recovered from JCOG0911, a randomized phase 2 trial for newly diagnosed glioblastoma (nGBM) conducted by the Japan Clinical Oncology Group (JCOG) Brain Tumor Study Group.

methodsThe correlation between tumor volumes and survival was evaluated, followed by progression-free survival (PFS) analysis by independent central review based on Response Assessment in Neuro-Oncology (RANO) criteria using MRI recovered from 118 nGBM patients enrolled in the JCOG0911 trial. A radiomic analysis was also performed to identify radiomic features predictive of nGBM prognosis.

resultsThe distribution of the Gd-enhancing and T2-weighted image/fluid attenuated inversion recovery-high intensity lesions mainly occupied white matter. JCOG0911 consisted of more subjects with right-sided lesions. The median extent of resection of the Gd-enhancing lesions was 99%. The overall survival showed a nonsignificant negative trend with postoperative Gd-enhancing lesion volume (P = 0.22), with the hazard ratio increasing in parallel with its volume. The median PFS after registration was 302 and 308 days for local Response Evaluation Criteria in Solid Tumors (RECIST)-based and central RANO-based diagnoses. However, an apparent discrepancy was observed between the two in the early phase, presumably due to the misdiagnosis of pseudoprogression by local RECIST-based diagnosis. Radiomic analysis identified 28 radiomic features predictive of nGBM prognosis, 5 of which were those previously identified in a separate cohort. The constructed radiomics-based prognostic model stratified the cohort into high- and low-risk groups (P = 0.028).

conclusionNovel analytical methods that could be incorporated into future clinical trials were successfully tested. RANO and RECIST may not differ in progression calls if pseudoprogression is appropriately handled.

Indexed as

Brain NeoplasmsGlioblastomaMagnetic Resonance ImagingAdultAgedBrainDisease ProgressionFemaleHumansJapanMaleMiddle AgedPrognosisProgression-Free SurvivalRadiomicsTumor Burdenglioblastomaprogression-free survivalradiomicsRANORECIST

Identifiers

PMID39567017
PMCPMC12671236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.